HIV-1 promoter is gradually silenced when integrated into
BACH2
CRISPR/Cas9
Genomic safe harbour AAVS1
HIV-1 integration
HIV-1 persistence
HIV-1-based, dual-fluorphore vector
Recurrent integration gene (RIG)
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
08
2020
accepted:
17
10
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
8
12
2020
Statut:
epublish
Résumé
The persistence of the latent HIV-1 reservoir is a major obstacle to curing HIV-1 infection. HIV-1 integrates into the cellular genome and some targeted genomic loci are frequently detected in clonally expanded latently HIV-1 infected cells, for instance, the gene We investigated HIV-1 promoter activity after integration into specific sites in Upon targeted integration of the 5.3 kb vector LTatCL[M] into Successful targeted integration of the HIV-1-based vector LTatCL[M] allows longitudinal analyses of HIV-1 promoter activity.
Sections du résumé
BACKGROUND
BACKGROUND
The persistence of the latent HIV-1 reservoir is a major obstacle to curing HIV-1 infection. HIV-1 integrates into the cellular genome and some targeted genomic loci are frequently detected in clonally expanded latently HIV-1 infected cells, for instance, the gene
METHODS
METHODS
We investigated HIV-1 promoter activity after integration into specific sites in
RESULTS
RESULTS
Upon targeted integration of the 5.3 kb vector LTatCL[M] into
CONCLUSION
CONCLUSIONS
Successful targeted integration of the HIV-1-based vector LTatCL[M] allows longitudinal analyses of HIV-1 promoter activity.
Identifiants
pubmed: 33282555
doi: 10.7717/peerj.10321
pii: 10321
pmc: PMC7694569
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10321Informations de copyright
© 2020 Inderbitzin et al.
Déclaration de conflit d'intérêts
Karin J. Metzner has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, Tibotec, Bristol-Myers Squibb, and Abbott; the University of Zurich has received research grants from Gilead, Roche and Merck Sharp & Dohme for studies that Karin J. Metzner serves as principal investigator, and advisory board honoraria from Gilead Sciences. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All other authors declare no competing interests relevant to this study.
Références
J Virol. 2011 Jun;85(11):5384-93
pubmed: 21430059
Cell Host Microbe. 2016 May 11;19(5):588-98
pubmed: 27173927
J Virol. 1997 Mar;71(3):2233-40
pubmed: 9032358
EMBO J. 1992 Dec;11(13):5071-8
pubmed: 1334463
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
Science. 2014 Jul 11;345(6193):179-83
pubmed: 24968937
Hum Gene Ther Methods. 2013 Apr;24(2):117-24
pubmed: 23448496
J Mol Biol. 2007 Nov 30;374(3):580-90
pubmed: 17945255
PLoS Biol. 2004 Aug;2(8):E234
pubmed: 15314653
AIDS. 2014 May 15;28(8):1091-9
pubmed: 24492253
Sci Rep. 2016 Apr 12;6:24157
pubmed: 27067385
Cell. 2015 Jan 29;160(3):420-32
pubmed: 25635456
Science. 1997 Nov 14;278(5341):1291-5
pubmed: 9360926
Nat Commun. 2017 Sep 8;8(1):498
pubmed: 28887441
Cell. 2002 Aug 23;110(4):521-9
pubmed: 12202041
Virus Res. 2018 Apr 2;249:69-75
pubmed: 29550509
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):549-53
pubmed: 7507249
Mol Ther. 2018 Feb 7;26(2):456-467
pubmed: 29273498
Curr HIV/AIDS Rep. 2015 Mar;12(1):88-96
pubmed: 25573791
J Biol Chem. 1989 Oct 5;264(28):16948-56
pubmed: 2476448
J Virol. 1996 Sep;70(9):6459-62
pubmed: 8709282
Cell Host Microbe. 2008 Aug 14;4(2):123-33
pubmed: 18692772
Mol Ther. 2016 Apr;24(4):678-84
pubmed: 26867951
Trends Genet. 2006 Jul;22(7):388-95
pubmed: 16730094
Biotechniques. 2015 Oct 01;59(4):201-2, 204, 206-8
pubmed: 26458548
Cell. 2013 Oct 24;155(3):519-29
pubmed: 24243012
Nat Rev Microbiol. 2011 Jul 04;9(8):617-26
pubmed: 21725337
J Immunol. 2016 Aug 15;197(4):1009-15
pubmed: 27496973
J Mol Biol. 2001 Oct 5;312(5):963-74
pubmed: 11580242
Am J Hum Genet. 1989 Dec;45(6):848-54
pubmed: 2573998
PLoS Pathog. 2015 Sep 17;11(9):e1005142
pubmed: 26379282
Nat Rev Cancer. 2011 Dec 01;12(1):51-8
pubmed: 22129804
Sci Rep. 2017 Jul 31;7(1):6913
pubmed: 28761140
Sci Rep. 2018 Jul 5;8(1):10204
pubmed: 29977044
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Immunity. 2017 Oct 17;47(4):766-775.e3
pubmed: 29045905
Science. 2014 Aug 1;345(6196):570-3
pubmed: 25011556
Nature. 2015 May 14;521(7551):227-31
pubmed: 25731161
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20
pubmed: 12843741
Cell Host Microbe. 2008 Aug 14;4(2):134-46
pubmed: 18692773
J Infect Dis. 2007 Mar 1;195(5):716-25
pubmed: 17262715